AN2 Therapeutics Inc.

NASDAQ: ANTX · Real-Time Price · USD
1.10
0.05 (4.27%)
At close: Aug 15, 2025, 3:04 PM

AN2 Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a n/a 77K n/a
Gross Profit
n/a n/a -77K n/a
Operating Income
-54.55M -69.64M -42.26M -21.57M
Interest Income
5.47M n/a 1.35M 69K
Pretax Income
-51.32M -64.73M -40.96M -21.54M
Net Income
-51.32M -64.73M -40.96M -21.54M
Selling & General & Admin
14.07M 14.76M 12.75M 4.67M
Research & Development
40.49M 54.87M 29.51M 16.91M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
54.55M 69.64M 42.26M 21.57M
Interest Expense
n/a n/a 514K n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
54.55M 69.64M 42.26M 21.57M
Income Tax Expense
n/a n/a n/a -69K
Shares Outstanding (Basic)
29.83M 23.6M 15.34M 18.74M
Shares Outstanding (Diluted)
29.83M 23.6M 15.34M 18.74M
EPS (Basic)
-1.72 -2.74 -2.79 -1.5
EPS (Diluted)
-1.72 -2.74 -2.79 -1.5
EBITDA
-51.32M 4.9M -40.88M -21.57M
EBIT
-51.32M -64.73M -40.96M -21.54M
Depreciation & Amortization
54.55M 69.64M 77K 21.57M